Geographical variation in incidence of prostate cancer in Sweden

References

• Available from: www.roc.se.
   Google Scholar
• Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol 2002; 20: 3–9
   PubMedGoogle Scholar
• Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60–7
   PubMed Web of Science ®Google Scholar
• Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981–90
   PubMed Web of Science ®Google Scholar
• Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 2002; 325: 740
   PubMedGoogle Scholar
• La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects. Urology 2003; 62: 1040–4
   PubMed Web of Science ®Google Scholar
• Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004; 93: 730–4
   PubMedGoogle Scholar
• De Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 237–44
   PubMed Web of Science ®Google Scholar
• Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden. Scand J Urol Nephrol 2003; 37: 461–5
   PubMed Web of Science ®Google Scholar
• McNaughton Collins M, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker Corkery E, et al. United States radiation oncologists’ and urologists’ opinions about screening and treatment of prostate cancer vary by region. Urology 2002; 60: 628–33
   PubMed Web of Science ®Google Scholar
• Fowler FJ, Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998; 104: 526–32
   PubMed Web of Science ®Google Scholar
• Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer 2003; 98: 1169–78
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber J-E, Hellström M, et al. The National Prostate Cancer Register in Sweden 1998–2002. Trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 117–23
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. HSI-health care information: register of health care units. 2003. Available from: www.scb.se.
   Google Scholar
• Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, et al. Prostate cancer registration in four Swedish regions 1996—differences in incidence, age structure and management. Scand J Urol Nephrol 1999; 33: 306–11
   PubMed Web of Science ®Google Scholar
• Johansson, J-E, Abrahamsson, P-A, Adami, H-O, Adolfsson, J, Carlsson, P, Damber, J-E, et al. Mass screening for prostate cancer. Report No. 126. 1995, ISBN 91-8790-30-J, Stockholm: Swedish Council on Technology Assessment in health care (SBU).
   Google Scholar
• Ferrini R, Woolf SH. American College of Preventive Medicine practice policy. Screening for prostate cancer in American men. Am J Prev Med 1998; 15: 81–4
   PubMed Web of Science ®Google Scholar
• National Health Service. Executive letter on population screening for prostate cancer EL 97, LeedsUK: NHS; 2002.
   Google Scholar
• Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, et al. EAU guidelines on prostate cancer; EAU Working Group on Oncological Urology. Eur Urol 2001; 2: 97–101
   Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61
   PubMed Web of Science ®Google Scholar
• Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 2004; 5: 220–5
   PubMedGoogle Scholar
• Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861–9
   PubMed Web of Science ®Google Scholar
• Magi-Galluzzi C, Epstein JI. Threshold for diagnosing prostate cancer over time. Hum Pathol 2003; 34: 1116–8
   PubMed Web of Science ®Google Scholar
• Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 1397–405
   PubMed Web of Science ®Google Scholar
• Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004; 108: 122–9
   PubMed Web of Science ®Google Scholar